Modality
mRNA
MOA
STINGag
Target
CD38
Pathway
STING
Melanoma
Development Pipeline
Preclinical
~May 2011
→ ~Aug 2012
Phase 1
~Nov 2012
→ ~Feb 2014
Phase 2
~May 2014
→ ~Aug 2015
Phase 3
~Nov 2015
→ ~Feb 2017
NDA/BLA
~May 2017
→ ~Aug 2018
Approved
Nov 2018
→ Apr 2029
ApprovedCurrent
NCT06163891
1,130 pts·Melanoma
2022-02→2029-04·Terminated
NCT04690405
2,652 pts·Melanoma
2018-11→TBD·Not yet recruiting
3,782 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2029-04-273.1y awayPh3 Readout· Melanoma
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
Approved
Not yet…
Approved
Termina…
Catalysts
Ph3 Readout
2029-04-27 · 3.1y away
Melanoma
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06163891 | Approved | Melanoma | Terminated | 1130 | Mayo |
| NCT04690405 | Approved | Melanoma | Not yet recr... | 2652 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| RHH-5389 | Roche | Preclinical | RET | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 |